CAR T Cell Therapy Market to Witness Widespread Expansion During 2020 to 2025

  CAR T Cell Therapy Market Analysis

The CAR T cell therapy market size is predicted to touch USD 8716.06 million at a 58.52% CAGR between 2019-2025, reveals the new Market Research Future (MRFR) report. CAR T cell therapy is amid the biggest breakthroughs and most promising treatment for cancer patients after chemotherapy. It is a form of immunotherapy where physicians gather immune cells from the patient, modify the same in the laboratory, and offer them the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. These infused cells multiply and remain in the patient’s body as living drugs. Short treatment time is one of the key benefits of CAR T cell therapy. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8102  

Numerous factors are adding to the CAR T cell therapy market demand. Such factors, as revealed by the latest MRFR report, include an increasing number of cell therapy clinical studies, growing pharmaceutical industry, technological advances for reliable and advanced treatment for cancer, and rising incidence of cancer both in adults & children worldwide. Additional factors adding to the CAR T cell therapy market growth include increasing initiatives by the government to promote cell therapy research in cancer and improve health care infrastructure and increasing approvals of CAR T cell therapies. 

On the contrary, high treatment costs and certain side effects that may cause CRS (cytokine release syndrome) and other forms of neurological problems, including delirium, hallucinations, coma, and seizures, are factors that may limit the CAR T cell therapy market growth over the forecast period. 

Market Segmentation

The Market Research Future’s CAR T cell therapy market report provides an inclusive segmental analysis of the CAR T cell therapy market on the basis of target antigen and application.

By target antigen, the CAR T cell therapy market has been segmented into CD22, CD19, & others. Among these, the CD19 target antigen segment will lead the market over the forecast period. It was valued USD 342.56 million in 2018. 

By application, the CAR T cell therapy market is segmented into diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and others. Of these, diffuse large B-cell lymphoma will have a major share in the market over the forecast period. 

Regional Analysis 

By region, the global CAR T cell therapy market covers the growth opportunities and recent trends across Europe, the US, China, and the Rest of the World. Of these, the US will dominate the market over the forecast period for the rapid development along with the launch of novel therapies by top industry players to treat cancer, and huge patient pool suffering from cancer. 

The CAR T cell therapy market in Europe is predicted to hold the second-largest share over the forecast period for extensive research & rising investment to develop cancer therapies, and rising prevalence of hematologic cancer especially multiple myeloma, lymphoma, and leukemia. 

The CAR T cell therapy market in China is predicted to have significant growth over the forecast period for the increasing disposable income and developing healthcare infrastructure. Besides, the rising number of CAR T cell therapy market companies signing and collaborating research and manufacturing contracts with the region’s local players for these therapies are also adding market growth. Cesca Therapeutics, for instance, signed an agreement in March 2018 with Boyalife Group in China for CAR-T cell-related manufacturing outsourcing, development, and bioprocessing. 

The CAR T cell therapy market in the RoW is predicted to have stable growth over the forecast period.

Key Players

Eminent players profiled in the CAR T cell therapy market report include Mustang Bio (US), Sorrento Therapeutics (US), Legend Biotech (US), Juno Therapeutics (US), Autolus Therapeutics PLC (UK), CARsgen Therapeutics (China), Cellectis (France), Pfizer, Inc. (US), Kite Pharma (US), and Novartis AG (Switzerland).

Industry News

March 2020: Tessa Therapeutics’ CD30-targeted CAR T-cell therapy has received RMAT designation by US FDA to treat refractory or relapsed classical Hodgkins lymphoma. Its benefits comprise early detections together with sponsors. 

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/car-t-cell-therapy-market-8102  

Global Theranostics Market to Record an Exponential CAGR by 2025

 Market Highlights

The global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period. Theranostics is a new field of medicine which combines therapeutics, nanoscience, and diagnostics based on specific targeted diagnostic tests. Theranostics is also called as theragnostics or companion diagnostics (CDx), or pharmacodiagnostics or personalized medical care, or personalized therapy, or personalized medicine technology. Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment. Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases. In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8057 

Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules. Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.

Segmentation

The global theranostics market has been segmented into the therapeutic area, technology, end user, and region.

By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others. The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.

On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others. The sequencing segment is likely to register comparatively higher CAGR over the forecast period due to the increasing number of proof-of-concept case studies and research related to sequencing, particularly next-generation sequencing (NGS) technology.

Based on end user, the market has been classified into hospitals and clinics, diagnostic laboratories, and others.

Key Players

Few of the prominent players in the global theranostics market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Focus Diagnostics, Abbott Laboratories, Illumina, Inc., Agilent Technologies, Inc., QIAGEN, Myriad Genetics, Inc., Foundation Medicine, Inc., and AmeriPath, Inc.

Regional Analysis

The global theranostics market has been categorized on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. On a regional basis, the Americas would command the market throughout the forecast period attributed to the domicile of major market participants, increasing research and development activities, and growing adoption of theranostics in the US and Canada. For instance, in June 2018, Genome Canada launched a national initiative for clinical implementation of precision health that would ultimately impact the market growth in the near future.

Europe would follow Americas in terms of value over the forecast period due to flourishing pharmaceutical and medical device companies, increasing partnerships and collaborations between life science companies and medical diagnostics companies, and growing personalized medicine sector. Personalized medicine (PM) is an emerging approach to prevention, diagnosis, treatment, and care which is assisting in addressing the challenge of the aging of the population, rising prevalence of chronic diseases, and increasing healthcare costs.

The market in Asia-Pacific would register the fastest market growth over next seven years owing to booming medical tourism, swiftly developing healthcare infrastructure, and growing awareness in the developing countries, namely, India, China, Singapore, and Australia.

The Middle East & Africa has the least share of the global theranostics market. In addition, the major market share of the region would be held by the Middle Eastern region due to developing healthcare system and medical infrastructure in the Arab countries.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/theranostics-market-8057 

Global Myelodysplastic Syndrome (MDS) Drugs Market to Record an Exponential CAGR by 2025

  Market Highlights

The Global Myelodysplastic Syndrome (MDS) drugs market is expected to grow significantly over the forecast period. The Myelodysplastic Syndrome (MDS) drugs market held a valuation of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period.

The increasing participation of key players is one of the key factors driving the Myelodysplastic Syndrome (MDS) drugs market. In 2018, the US Food and Drug Administration approved generic injectable product decitabine for Lupin Ltd. There are various other MDS medications available in the market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8134 

Various other factors that are driving the MDS drugs market are the promotion of clinical studies related to MDS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufactures.

However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast period.

Segmentation

The global Myelodysplastic Syndrome (MDS) drugs market is segmented based on product, type of syndrome, route of administration, end user, and region.

Based on product, the global Myelodysplastic Syndrome (MDS) drugs market is further segmented into chemotherapy, immunomodulatory drugs, and others. The chemotherapy segment is sub-segmented as conventional drugs and hypomethylating drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional drugs comprise Cytarabine, Daunorubicin, and Idarubicin.

The MDS drugs market at a global level is segmented on type of syndrome into refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and others.

Based on the route of administration, the market is segmented into oral, parenteral, and others. The MDS drugs available in the market are administered through parenteral route, for instance, intravenous or subcutaneous. The parental route has a quick effective after administration. Thus, the parenteral segments have greater growth compared to the other dosage forms in this segment. Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. MDS patients are treated in the hospitals, clinics, and ambulatory surgical centers. MDS drugs are prescribed by physicians to patients, as in critical conditions, it could lead to blood cancer. The hospitals segment holds the major share in this segment as it deals with a larger number of MDS patients compared to clinics and ambulatory surgical centers.

Key Players

Various players operate in the global Myelodysplastic Syndrome (MDS) Drugs market such as BluePoint Laboratories, Celgene Corporation, Celgene Europe Limited, Dr. Reddy's Laboratories Inc., Johnson & Johnson, Lupin Ltd Corporation, Otsuka America Pharmaceutical Inc, Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries Inc, and others.

Regional Analysis

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The global MDS drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European global MDS drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The MDS drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The global Myelodysplastic Syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/myelodysplastic-syndrome-drugs-market-8134 

Dental Restorative and Regenerative Material Market Estimated to Witness a Staggering Growth by 2023

  The Global Dental Restorative and the Regenerative Material Market are expected to register a CAGR of 6.7% and is anticipated to reach USD 2679.7 Million by 2023. 

Dental restorative and regenerative materials are used to replace damaged or lost teeth, mostly it happens due to dental caries or dental cavities. Simultaneously, dental restorative and regenerative materials are also used in cosmetic dentistry, which improves the appearance of the teeth and enhances the smile of an individual.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/4332  

The increasing prevalence of dental disorders, availability of identical material, growing dental tourism, rising adherence and biocompatibility, and increasing disposable income are responsible for propelling the market growth. However, the high cost of dental restorative and regenerative material and lack of awareness about dental procedures are hampering the growth of the market.

Market Dynamics

The rise in the cases of dental complications is expected to drive the growth of the market. According to the World Dental Federation, more than 3.9 billion people are affected by oral diseases, and about half of the world’s population is suffering from untreated tooth decay. Moreover, increasing dental tourism is also likely to support market growth. On the other hand, the high cost of dental materials and lack of awareness is anticipated to hamper the market growth.

Segmentation

The global dental restorative and the regenerative material market has been segmented into type and end user. By type, the market has been segmented into restorative material and regenerative material. Restorative material segment has been divided into an amalgam, resin-base composite, glass ionomer, resin-modified glass ionomer, porcelain, metal, porcelain-fused-to-metal. The regenerative material segment is further segmented into bone graft materials, membranes, and tissue regeneration products.  

Based on end user, the market has been segmented into dental research laboratories and dental hospitals and clinics. The dental hospitals and clinics segment accounted for a market share of 82.30% in 2016.

Key Players

The prominent players in the global dental restorative and regenerative material market are DENTSPLY Sirona, Henry Schein, Inc., Kerr Corporation, Keystone Dental, Inc., Nobel Biocare Services AG, 3M, Biotech Dental, botiss biomaterials GmbH, Institut Straumann AG, and Zimmer Biomet.

Some of the key strategies followed by the players operating in the global dental restorative and regenerative material market were innovation, product development, acquisition, and expansion.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/dental-regenerative-material-market-4332

Malocclusion Market – Product Development is the best strategy for market position; Forecast till 2023

  Market Scenario

Malocclusion refers to the misalignment of teeth that can lead to serious oral health complications. Malocclusion is commonly hereditary, but it can also occur due to other reasons i.e. childhood habits such as thumb sucking, pacifier use beyond age 3, extra teeth or lost teeth, ill-fitting dental fillings, and jaw tumors. There are three major manifestations of malocclusion i.e. Class 1, Class 2, and Class 3. Class 1 malocclusion is the most common among all types. Treatment for malocclusion depends upon the severity of the condition. Treatment of malocclusion generally includes removal of teeth to correct overcrowding, braces to correct the position of the teeth, wires or plates to stabilize the jaw bone, reshaping, bonding, or capping of teeth, and surgery to reshape or shorten the jaw.

It is noted that rising prevalence of malocclusion is the key factors driving the malocclusion market. According to a study published in International Journal of Environmental Research and Public Health in 2017, it was found that prevalence of malocclusion in Shanghai is 83.9%. It is also reported that the prevalence of deep overbite was the highest in children with malocclusion i.e. 63.7%. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5094

Improvement in reimbursement scenario, and the rising trend of cosmetic dentistry are also fuelling the market growth. The techniques used for the repairing various irregularities such as discoloration, chipped teeth, and misshapen teeth or missing teeth are greatly impacting the growth of the market.

However, lack of technological awareness, and slow adoption rate in low-income countries may strongly hinder the growth of the market

The global malocclusion market is expected to grow at a CAGR of 7.0% during the forecast period 2017-2023.

Intended Audience

• Medical Devices Companies
• Hospitals & Clinics
• Diagnostic Centers
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities 

Segmentation

The global malocclusion market is segmented on the basis of class, treatment, and end user.

On the basis of the class, the market is classified into class I, class II, and class III.

On the basis of the treatment, the market is segmented into orthodontic braces, surgery, and others. The orthodontic braces segment is further sub-segmented into metal braces, ceramic braces, clear aligner, and others.

On the basis of the end-users, the market is segmented into hospital, clinics, dental clinics, and others.

Key Findings

• The global malocclusion market is expected to reach USD 27,720.8 million by 2023 at a CAGR of 7.0%
• On the basis of the class, Class I malocclusion is expected to command the largest market share of 41.7% over the review period and it is also expected to grow at the fastest CAGR of 7.2% during the forecast period 2017-2023
• On the basis of the treatment, orthodontic braces segment is expected to command the largest market share of 65.5% over the review period and it is also expected to grow at the fastest CAGR of 7.3% during the forecast period 2017-2023
• The Americas hold the largest share of the global malocclusion market and is expected to reach USD 11,098.3 million by 2023
• Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 7.3% over the 2017-2023

 

Regional Analysis

The Americas dominate the malocclusion market owing to improvements in reimbursement scenario, high healthcare expenditure, and the presence of leading players in the region. According to the American Dental Association, in the United States, Maryland, Utah, Arkansas, and Massachusetts have the highest Medicaid FFS reimbursement rates i.e. 79.3%, 75.3%, 75.2%, and 74.1% respectively, whereas, Wisconsin, California, Washington, Maine, and Iowa have the lowest coverage relative to private dental insurance reimbursement rates.

Europe holds the second position in the malocclusion market. It is expected that the support provided by the government bodies for research & development, increasing healthcare expenditure, and rising prevalence of malocclusion are propelling the growth of the malocclusion market in European region. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.

Asia Pacific region is projected to be the fastest growing region during the forecast period. Rapidly improving technology and the presence of huge patient pool drive the growth of this market in Asia Pacific region.

The Middle East and Africa hold the least share of the malocclusion market owing to the presence of poor and slow developing countries, especially, in African region.

Key Players

Some of key the players in the malocclusion market are 3M, A-dec Inc., Adenta GmbH, Align Technology, Inc, American Orthodontics, Biolase, Inc., Carestream Health, Inc., Danaher, DENTAURUM GmbH & Co. KG, Dentsply Sirona, G&H Orthodontics, Henry Schein, Inc., Midmark Corp., Patterson Companies, Inc., Planmeca OY, Rocky Mountain Orthodontics, Septodont Holding, TP Orthodontics, Inc, Ultradent Products Inc., Zimmer Dental Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/malocclusion-market-5094

Dental Software Market Foreseen to Draw a Promising Growth by 2023

  Dental Software Market Analysis

The global dental software market can reach a valuation of USD 4,185.5 billion by 2027. It is predicted to expand at a CAGR of 8% over the forecast period. Technological advances in dental imaging and the large geriatric populace are two of the biggest drivers of the market. According to the UNFPA, the geriatric population can reach a number of 1.3 billion by 2050. In addition, their low immunity makes them vulnerable to oral health diseases.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/675

Rise of dental surgeries, adoption of digital dental radiography systems, and advances in dental equipment can fuel the demand for dental software. Moreover, the large number of dentists and dental clinics can drive the demand for software for tracking appointments and providing prime customer service. Efficiencies in dental operations and use of intraoral cameras to gain accurate images of the mouth can bode well for the market.

High prices of digital dental system and complexities in the operation of the system can impede the market growth.

Dental Software Market Segmentation

The global dental software market has been segmented into type, application, and deployment.

Based on type, the market has been segmented into patient education software, practice management software, treatment planning software, patient communication software, and dental imaging software.

Major applications of the market are clinical application and administrative.

Based on deployment, the market is divided into on-premise model and web-based/cloud-based model.

Dental Software Market Regional Analysis

Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are regions taken into consideration with respect to the global dental software market.

The Americas held the largest market share owing to government support in assisting the dental industry in thriving. The U.S. held a share of 88% in North America in 2015. Large numbers of orthodontists and dental clinics can create demand for dental software.

Europe can showcase substantial growth in the market owing to awareness of the benefits of oral health and various options for cosmetic dentistry. APAC, on the other hand, can grow at a rapid pace owing to a plethora of opportunities for dental software in countries such as Japan and others.

Dental Software Market Competition Outlook

Planmeca oy, Datacon Dental Systems, Open Dental Software Inc., Ace Dental Software, Sirona Dental Systems, Inc., Dentimax LLC, Abeldent Inc., Carestream Health, Inc., Consult-pro, Henry Schein, Inc., Medicloud, Patterson Dental, Dexis, LLC, Imageworks Corporation, and Gendex Dental System are key players of the global dental software market.

Dental Software Industry News

A new software has been developed for the easy detection of the mandibular canal, a canal located in both sides of the jaw. Artificial intelligence has been integrated into the software for easy detection by scientists at the Finnish Center for Artificial Intelligence and Alan Turing Institute by training the software to recognize it by feeding 3D cone beam CT data scans.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/global-dental-software-market-675 

Dental Implants Market is expected to rise at a remarkable CAGR By 2023

  Global Dental Implants Market is expected to register a CAGR of 4.6%and is anticipated to reach USD 6229.8 million by 2023.

Dental implant is the option for those people who have lost their tooth or teeth, owing to an injury, periodontal disease or some other reasons. It is an artificial tooth root that allow dentist to mount the replacement of teeth, by placing it into the jaw.  The dental implant is a metal post made up of titanium which help in surgeries beneath the gums. According to a report published by the Centers for Disease Control and Prevention, in 2015, around 84.7% of children aged 2-17 years, have visited dentist for checkup, and more than 62.7% of adults aged above 65 years have visited  dentist for dental implants.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2753 

Global Dental implants Market – Overview

The global dental implants market is rising with a swift phase; mainly owing to increase in patient population. According to the World Health Organization (WHO), in 2014, around 30% of the older aged (65-74) population globally have lost their natural teeth, around 60-90% of the school children globally and nearly 100% of the adults were believed to have dental cavities, about 15-20% middle aged (35-44 years) adults have found to have severe periodontal disease. Increasing consumer awareness about technology associated with oral health and rapidly increasing population globally leads to the growth of the dental implant market. Dentistry as a branch of healthcare has also further expanded and developed in its sub branches resulting in specialist oral care depending upon the type of treatment required for the oral care. Major specializations are orthodontics, endodontics, prosthodontics, and periodontics

Companies are continuously inventing in new products to capture the market globally. Thus, major players invest more in research and development activities, in order to lead the global market. In this regards, Osstem Implant, in 2015, invested in research and development to push for invention in the field of dental implants and persistently develops state-of-the-art products and thus, becoming the leader and the ‘First Mover’ in global dental implant market. Osstem Implant is also focusing on the expansion of sales network globally, advancement in education programs, and strategies for marketing.

In 2016, Zimmer Biomet dental division has introduce new technology of dental implants, and there surgical and restorative components. The company introduce 3.1-mmD Eztetic implant, which add-on improvement on existing available implants. According to the company, this product achieved a 43% higher fatigue strength in comparison to selected competitive implants of similar technical features. Increasing in genetic population globally and consumption of tobacco are the factors that leads the market of dental implants. Moreover companies are more focus to capture the market.

Competitive Analysis

Institut Straumann AG (Switzerland), 3M (U.S.), Osstem Implant (South Korea), Nobel Biocare (Part of Danaher corporation (U.S.), Dentsply Sirona (U.S.), Zimmer Biomet (U.S.), CAMLOG Biotechnologies AG (Switzerland), Neobiotech Inc. (U.S.) are some of the leading players at the cutting edge of the competition in the market of dental implants, globally.

Global Dental Implants Market   - Regional Analysis

The market of dental implants is much higher in the Americas region. There are huge population which are missing all their teeth in one or both jaws. According to a report published in 2014, by the National Institute of Dental and Craniofacial Research, government initiated the National Oral Health Plan to improve the quality of life of the Americans. Through this program they were focusing on change in public perceptions, change in policymakers' perceptions, and change in health providers' perceptions.

Europe is also considered a huge market for dental implants players, owing to presence of huge population affected with oral diseases. Governments are more focusing on educating their public in order to minimize the patient’s population by educating them about the relationship between mouth and rest of the body.

Asia Pacific and the Middle East and Africa region are considered untapped markets. Whereas, country like India and China of Asia Pacific region are considered as the fastest growing region due to presence of huge population suffering with oral health issues. Japan is well developed country and have well established healthcare system and technology, whereas developing countries are still focusing on new drugs and technology for the treatment of dental implants, this gap between the developed and developing countries will present significant growth opportunity for the dental implants market players in the coming years. Additionally, they are open to adopt new technology and best treatment option from developed countries in order to improve the quality of life for their public. Whereas, the Middle East and Africa are low growth market due to lack of investment.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/dental-implants-market-2753